Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: ISIS-FXIRx Dose #3
Drug: ISIS-FXIRx Dose #2
Drug: Enoxaparin

First Posted Date: 2012-10-24

Last Posted Date: 2014-08-27

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 315

Registration Number: NCT01713361

Locations: 🇺🇦
Isis Investigational Site, Sevastopol, Ukraine

Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin

Phase 3

Completed

Conditions: Thromboprophylaxis in Hospitalized Obese Patients

Interventions: Drug: Enoxaparin

First Posted Date: 2012-10-16

Last Posted Date: 2015-06-18

Lead Sponsor: University Hospital, Rouen

Target Recruit Count: 92

Registration Number: NCT01707732

Locations: 🇫🇷
UH Rouen, Rouen, France

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

Not Applicable

Completed

Conditions: Soft Tissue Sarcoma
Bone Metastases
Musculoskeletal Cancer
Thromboembolism

Interventions: Drug: acetylsalicylic acid
Drug: enoxaparin
Device: PCD

First Posted Date: 2012-10-01

Last Posted Date: 2018-12-05

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT01696760

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)

Not Applicable

Completed

Conditions: Traumatic Intracranial Haemorrhage

Interventions: Other: Placebo
Drug: Enoxaparin

First Posted Date: 2012-05-02

Last Posted Date: 2018-03-22

Lead Sponsor: McMaster University

Target Recruit Count: 52

Registration Number: NCT01589393

Locations: 🇨🇦
Hamilton Health Sciences- General site, Hamilton, Ontario, Canada

Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

Not Applicable

Completed

Conditions: Venous Thromboembolic Diseases

Interventions: Drug: Bemiparin
Drug: Enoxaparin

First Posted Date: 2012-04-30

Last Posted Date: 2015-03-18

Lead Sponsor: Hawler Medical University

Target Recruit Count: 7020

Registration Number: NCT01588171

Locations: 🇮🇶
Hawler medical university, Erbil, Kurdistan region, Iraq

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Phase 3

Completed

Conditions: Venous Thromboembolism (VTE)

Interventions: Drug: Betrixaban
Drug: Enoxaparin

First Posted Date: 2012-04-23

Last Posted Date: 2023-08-07

Lead Sponsor: Portola Pharmaceuticals

Target Recruit Count: 7513

Registration Number: NCT01583218

PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients

Phase 3

Terminated

Conditions: Hemorrhagic Stroke
Venous Thromboembolism
Deep Venous Thrombosis

Interventions: Other: Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
Drug: Enoxaparin

First Posted Date: 2012-04-06

Last Posted Date: 2021-09-10

Lead Sponsor: University Of Perugia

Target Recruit Count: 73

Registration Number: NCT01573169

Locations: 🇮🇹
Stroke Unit, Perugia, Italy

Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery

Phase 3

Withdrawn

Conditions: Asymptotic Venous Thrombosis

Interventions: Drug: Enoxaparin

First Posted Date: 2011-11-18

Last Posted Date: 2013-08-27

Lead Sponsor: The Hospital for Sick Children

Registration Number: NCT01474902

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Completed

Conditions: Thrombosis, Venous

Interventions: Drug: dalteparin
Drug: enoxaparin
Drug: fondaparinux
Drug: unfractionated heparin

First Posted Date: 2011-10-03

Last Posted Date: 2017-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4068

Registration Number: NCT01444612

Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy

Phase 3

Completed

Conditions: Placental Insufficiency
High Risk Pregnant Women
Preeclampsia

Interventions: Drug: Enoxaparin

First Posted Date: 2011-07-06

Last Posted Date: 2016-12-21

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 361

Registration Number: NCT01388322

Locations: 🇪🇸
Hospital de Cruces, Barakaldo, Vizcaya, Spain
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇪🇸
Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy